Advanced

High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.

Nordengren, Johanna LU ; Fredstorp Lidebring, Margareta; Bendahl, Pär-Ola LU ; Brünner, Nils; Fernö, Mårten LU ; Högberg, Thomas; Stephens, Ross W; Willén, Roger and Casslén, Bertil LU (2002) In International Journal of Cancer 97(3). p.379-385
Abstract
Previous studies including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival. High tumor tissue concentrations of PAI-2 have been associated with good prognosis in patients with breast cancer, small cell lung cancer and ovarian cancer, but with poor histologic differentiation and poor prognosis in patients with colorectal cancer. On the other hand, high tumor tissue concentrations of urokinase plasminogen activator (uPA), uPA receptor (R) and PAI-1 have more consistently been associated with poor histologic differentiation and poor prognosis. Our study quantified PAI-2 and uPAR using specific enzyme-linked immunosorbent assays in homogenates... (More)
Previous studies including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival. High tumor tissue concentrations of PAI-2 have been associated with good prognosis in patients with breast cancer, small cell lung cancer and ovarian cancer, but with poor histologic differentiation and poor prognosis in patients with colorectal cancer. On the other hand, high tumor tissue concentrations of urokinase plasminogen activator (uPA), uPA receptor (R) and PAI-1 have more consistently been associated with poor histologic differentiation and poor prognosis. Our study quantified PAI-2 and uPAR using specific enzyme-linked immunosorbent assays in homogenates of 274 samples of endometrial cancer tissue. The prognostic power of each factor was analyzed in the subgroup of patients with early stage disease, i.e., International Federation of Gynecology and Oncology (FIGO) surgical stage I-II (n = 188). This group had a median follow-up time of 6.8 years (range 0.7-9.9), and 23 progressions were observed. The 80(th) percentile for PAI-2 and uPAR was used to dichotomize the material, and the results were analyzed for associations with clinical data including progression-free survival. The results were also compared with DNA ploidy status, S-phase fraction, uPA and PAI-1, which we reported in a previous study (Fredstorp Lidebring et al., Eur J Cancer 2001; in press). A high PAI-2 level was associated with shorter progression-free survival in univariate analysis and was an independent prognostic factor in bivariate analyses, which included PAI-1, uPA and DNA ploidy status. In contrast, a high level of uPAR had no association with prognosis in early stage endometrial cancer. The combination of high PAI-2 and PAI-1 levels in tumors revealed a small group of stage I-II patients with an accumulative progression rate of 50%. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Endometrial Neoplasms : diagnosis : metabolism : pathology, Female, Human, Middle Age, Plasminogen Activator Inhibitor 2 : biosynthesis, Prognosis, Time Factors, Support Non-U.S. Gov't, Disease-Free Survival, Disease Progression, Cytosol : metabolism, Aged, Adult
in
International Journal of Cancer
volume
97
issue
3
pages
379 - 385
publisher
John Wiley & Sons
external identifiers
  • pmid:11774293
  • wos:000172996300019
  • scopus:0037137848
ISSN
0020-7136
DOI
10.1002/ijc.1611
language
English
LU publication?
yes
id
45d4d829-337c-42aa-bfb7-5072855d132a (old id 106868)
alternative location
http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11774293&dopt=Abstract
date added to LUP
2007-07-18 10:54:40
date last changed
2017-11-12 03:20:32
@article{45d4d829-337c-42aa-bfb7-5072855d132a,
  abstract     = {Previous studies including various tumor types have shown different associations between tumor tissue levels of plasminogen activator inhibitor 2 (PAI-2) and patient survival. High tumor tissue concentrations of PAI-2 have been associated with good prognosis in patients with breast cancer, small cell lung cancer and ovarian cancer, but with poor histologic differentiation and poor prognosis in patients with colorectal cancer. On the other hand, high tumor tissue concentrations of urokinase plasminogen activator (uPA), uPA receptor (R) and PAI-1 have more consistently been associated with poor histologic differentiation and poor prognosis. Our study quantified PAI-2 and uPAR using specific enzyme-linked immunosorbent assays in homogenates of 274 samples of endometrial cancer tissue. The prognostic power of each factor was analyzed in the subgroup of patients with early stage disease, i.e., International Federation of Gynecology and Oncology (FIGO) surgical stage I-II (n = 188). This group had a median follow-up time of 6.8 years (range 0.7-9.9), and 23 progressions were observed. The 80(th) percentile for PAI-2 and uPAR was used to dichotomize the material, and the results were analyzed for associations with clinical data including progression-free survival. The results were also compared with DNA ploidy status, S-phase fraction, uPA and PAI-1, which we reported in a previous study (Fredstorp Lidebring et al., Eur J Cancer 2001; in press). A high PAI-2 level was associated with shorter progression-free survival in univariate analysis and was an independent prognostic factor in bivariate analyses, which included PAI-1, uPA and DNA ploidy status. In contrast, a high level of uPAR had no association with prognosis in early stage endometrial cancer. The combination of high PAI-2 and PAI-1 levels in tumors revealed a small group of stage I-II patients with an accumulative progression rate of 50%.},
  author       = {Nordengren, Johanna and Fredstorp Lidebring, Margareta and Bendahl, Pär-Ola and Brünner, Nils and Fernö, Mårten and Högberg, Thomas and Stephens, Ross W and Willén, Roger and Casslén, Bertil},
  issn         = {0020-7136},
  keyword      = {Endometrial Neoplasms : diagnosis : metabolism : pathology,Female,Human,Middle Age,Plasminogen Activator Inhibitor 2 : biosynthesis,Prognosis,Time Factors,Support Non-U.S. Gov't,Disease-Free Survival,Disease Progression,Cytosol : metabolism,Aged,Adult},
  language     = {eng},
  number       = {3},
  pages        = {379--385},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.},
  url          = {http://dx.doi.org/10.1002/ijc.1611},
  volume       = {97},
  year         = {2002},
}